Hospital
West Valley Medical Center, INC.
West Valley Medical Center, INC. was paid $7.84M by Medicaid between Jan 2018 and Nov 2024, across 175 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoWEST VALLEY MEDICAL CENTER, INC.
CALDWELL, ID 83605
CALDWELL, ID 83605
33aNPI1891732905assigned 05/31/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$7.84M
24GClaims208,656
24DCodes billed175
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 81,260 | $2.68M | |
| 2019 | 69,548 | $2.98M | |
| 2020 | 44,791 | $2.07M | |
| 2021 | 4,100 | $57K | |
| 2022 | 4,254 | $31K | |
| 2023 | 3,153 | $12K | |
| 2024incomplete | 1,550 | $10K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 13,704 | 12,666 | $1.94M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 8,927 | 7,882 | $1.65M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.2% | 9,736 | 3,079 | $564K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 2,016 | 1,804 | $510K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 4,075 | 3,912 | $350K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.1% | 4,751 | 1,721 | $244K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.0% | 2,768 | 2,672 | $233K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.5% | 2,937 | 2,460 | $197K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 1,513 | 1,400 | $178K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 6,156 | 5,317 | $175K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 5,049 | 4,261 | $131K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 472 | 446 | $100K |
163 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.3% | 1,299 | $98K |
| 80053 | Comprehensive metabolic panel | 1.2% | 13,353 | $91K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 2,123 | $79K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,410 | $69K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,828 | $67K |
| 85027 | <1% | 16,302 | $66K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,815 | $58K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 908 | $50K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,360 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,095 | $40K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,089 | $39K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,975 | $37K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,160 | $34K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,133 | $27K |
| 92523 | <1% | 195 | $27K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 675 | $26K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,074 | $25K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 557 | $25K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,676 | $25K |
| 94664 | <1% | 931 | $22K | |
| 87634 | <1% | 298 | $22K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 49 | $21K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,795 | $20K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 378 | $20K |
| 84484 | <1% | 3,827 | $19K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 192 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 354 | $19K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 334 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,646 | $17K |
| 83690 | <1% | 2,902 | $16K | |
| 12001 | <1% | 102 | $16K | |
| 83880 | <1% | 998 | $16K | |
| 80055 | <1% | 300 | $15K | |
| 81001 | <1% | 5,725 | $15K | |
| 81025 | <1% | 2,026 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,615 | $13K |
| 84703 | <1% | 1,786 | $13K | |
| 76830 | Ultrasound, transvaginal | <1% | 204 | $12K |
| 80061 | Lipid panel | <1% | 1,500 | $12K |
| 87430 | <1% | 863 | $12K | |
| 84439 | <1% | 1,501 | $11K | |
| 97162 | <1% | 292 | $11K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 272 | $10K |
| 74018 | <1% | 828 | $10K | |
| 76801 | <1% | 179 | $10K | |
| 84702 | <1% | 646 | $10K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 285 | $9K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 44 | $8K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 37 | $8K |
| 87150 | <1% | 148 | $8K | |
| 83605 | <1% | 1,153 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 270 | $8K |
| 73610 | <1% | 502 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,216 | $7K |
| 87040 | <1% | 975 | $7K | |
| 87653 | <1% | 170 | $7K | |
| 73562 | <1% | 427 | $7K | |
| 87186 | <1% | 970 | $6K | |
| 86140 | <1% | 1,320 | $6K | |
| 73110 | <1% | 244 | $4K | |
| 93017 | <1% | 58 | $4K | |
| 87081 | <1% | 713 | $4K | |
| 81003 | <1% | 2,211 | $4K | |
| 73630 | <1% | 319 | $4K | |
| 72100 | <1% | 340 | $4K | |
| 86701 | <1% | 425 | $4K | |
| 93971 | <1% | 58 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 45 | $3K |
| 84145 | <1% | 225 | $3K | |
| 73130 | <1% | 206 | $3K | |
| V2632 | Posterior chamber intraocular lens | <1% | 96 | $3K |
| 85610 | <1% | 1,049 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 77 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 79 | $3K |
| 85379 | <1% | 350 | $3K | |
| 88304 | <1% | 74 | $3K | |
| 85730 | <1% | 613 | $3K | |
| 80076 | <1% | 462 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,539 | $2K |
| 73030 | <1% | 200 | $2K | |
| 82728 | <1% | 248 | $2K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $2K |
| 87070 | <1% | 317 | $2K | |
| 12011 | <1% | 14 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,166 | $2K |
| 87486 | <1% | 49 | $2K | |
| 87581 | <1% | 49 | $2K | |
| 83735 | <1% | 448 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 158 | $2K |
| 99153 | Mod sedat endo service >5yrs | <1% | 36 | $2K |
| 85652 | <1% | 646 | $1K | |
| 87210 | <1% | 317 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 913 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,845 | $1K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $1K |
| 87280 | <1% | 102 | $1K | |
| 82947 | <1% | 325 | $1K | |
| 73140 | <1% | 72 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 30 | $1K |
| 85018 | <1% | 492 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 56 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 77 | $1K |
| 82607 | <1% | 80 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,371 | $1K |
| 99152 | <1% | 38 | $992.39 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $918.56 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,551 | $911.41 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 14 | $879.97 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $836.44 |
| 83550 | <1% | 140 | $820.88 | |
| 83540 | <1% | 174 | $780.83 | |
| G0378 | Hospital observation service, per hour | <1% | 482 | $763.52 |
| 86901 | <1% | 297 | $745.49 | |
| 90715 | <1% | 36 | $724.36 | |
| 86900 | <1% | 237 | $617.54 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $541.97 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 16 | $541.07 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 281 | $536.06 |
| 82550 | <1% | 110 | $520.29 | |
| 72110 | <1% | 41 | $506.44 | |
| 76642 | <1% | 18 | $505.53 | |
| 86850 | <1% | 131 | $503.97 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,215 | $484.67 |
| 36000 | <1% | 107 | $389.10 | |
| 73080 | <1% | 26 | $371.60 | |
| 82043 | <1% | 120 | $365.83 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 374 | $316.39 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 14 | $310.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 633 | $286.56 |
| 84100 | <1% | 115 | $232.54 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 297 | $222.68 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 128 | $214.42 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 426 | $214.15 |
| 84481 | <1% | 12 | $209.20 | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 264 | $192.75 |
| 73090 | <1% | 13 | $184.47 | |
| 73502 | <1% | 18 | $180.57 | |
| 73590 | <1% | 12 | $169.81 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 31 | $161.70 |
| 82150 | <1% | 25 | $151.90 | |
| 87641 | <1% | 18 | $126.18 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,880 | $124.25 |
| J2704 | Injection, propofol, 10 mg | <1% | 219 | $116.11 |
| 76937 | <1% | 34 | $104.32 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 273 | $90.75 |
| 85014 | <1% | 27 | $81.66 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 350 | $77.64 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 82 | $70.06 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 81 | $61.56 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,249 | $49.76 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 342 | $49.01 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 19 | $41.12 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 13 | $40.32 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 89 | $9.14 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 26 | $7.12 |
| 96376 | <1% | 908 | $4.52 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 22 | $3.60 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 206 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,844 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 27 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 18 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 69 | $0.00 |
| 87400 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUCKS, JARED (CFO)